bms-200

BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM.

Epolactaene is a neuritogenic compound in human neuroblastoma cells which selectively inhibit the activities of mammalian DNA polymerases and human DNA topoisomerase II.

Entecavir monohydrate (BMS-200475) is a selective inhibitor of the replication of the hepatitis B virus (HBV). It, a new deoxyguanine nucleoside analog.

Entecavir (SQ34676) is a guanosine nucleoside analogue used in the treatment of chronic hepatitis B virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis B during or after therapy, but has not been linked to cases of clinically apparent liver injury.

IACS-4759 is a novel potent and selective MTH1 inhibitor with excellent cell permeability and good metabolic stability in microsomes.

BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor exhibiting IC50 values ranging from 18 to 200 nM against the PD-L1/PD-1 complex, while displaying nonspecific cytotoxicity toward modified Jurkat T cells with EC50 values between 3 and 6 μM, and it is widely used to investigate PD-L1–induced T-cell exhaustion mechanisms or as a PD-L1 ligand scaffold for the rational design and synthesis of PROTAC molecules in immuno-oncology research.